NCT01915784View on ClinicalTrials.gov

Preference, Satisfaction and Ease of Use of Genuair® (Pressair™) and Breezhaler® (Neohaler™) Inhalers in Patients With COPD

PHASE3CompletedINTERVENTIONAL
Enrollment

128

Participants

Timeline

Start Date

July 31, 2013

Primary Completion Date

October 31, 2013

Study Completion Date

October 31, 2013

Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
DEVICE

Genuair®

Inhaler with placebo only. Once daily, for 14 days.

DEVICE

Breezhaler®

Inhaler with placebo only. Once daily, for 14 days.

Trial Locations (6)

Unknown

Almirall investigative site 2, Berlin

Almirall investigative site 1, Munich

Almirall investigative site 3, Barcelona

Almirall investigative site 4, Palma de Mallorca

Almirall investigative site 5, Glasgow

Almirall investigative site 6, Newcastle upon Tyne

Sponsors

Lead Sponsor

Almirall, S.A.

Collaborators (1)

Forest Laboratories
All Listed Sponsors
collaborator

Forest Laboratories

INDUSTRY

lead

Almirall, S.A.

INDUSTRY

NCT01915784 - Preference, Satisfaction and Ease of Use of Genuair® (Pressair™) and Breezhaler® (Neohaler™) Inhalers in Patients With COPD | Biotech Hunter | Biotech Hunter